drugset / Trial / NCT01065012
Treatment of Erectile Dysfunction - Long Term Safety and Efficacy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Open-Label Phase 3 study to evaluate the long-term safety and efficacy of udenafil, an orally administered selective inhibitor of PDE-5 for the treatment of subjects with erectile dysfunction (ED).
Timeline
- Start
- 2010-01
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Udenafil | Small molecule | 50 mg | Oral |
| Subject | Udenafil | Small molecule | 100 mg | Oral |
| Subject | Udenafil | Small molecule | 150 mg | Oral |